The fourth-quarter earnings season for the biotech sector is in full swing this week. A few bigwigs have already reported results. Among these, Bristol Myers reported better-than-expected ...

Beyond analysts' top -and-bottom-line estimates for Alnylam (ALNY), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ...

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) has received an average recommendation of “Moderate Buy” from ...

SG Americas Securities LLC cut its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 50.8% ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Liquidity indicates a company’s capability to meet debt obligations by converting its assets into liquid cash and equivalents. A company with adequate liquidity always has the potential to deliver ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

View Alnylam Pharmaceuticals, Inc. (ALNY) current and estimated P/E ratio data provided by Seeking Alpha.

The United States market has shown robust performance recently, climbing 3.0% in the last week and achieving a 25% increase over the past year, with earnings expected to grow by 15% annually. In this ...

Alnylam Pharmaceuticals (Alnylam) is a biopharmaceutical company, which discovers, develops, and commercializes drugs based on RNAi interference. The company’s marketed RNAi therapies include Onpattro ...